

## Singapore's STCC enters imCORE Network to advance cancer research and therapeutics

24 July 2024 | News

**Singapore Translational Cancer Consortium (STCC) aims to catalyze and boost R&D around Cancer Immuno Therapeutics (CIT) through imCORE Network, a global initiative**



Singapore Translational Cancer Consortium (STCC) enters into a new alliance with Roche/Genentech-led, immunotherapy Centers Of Research Excellence (imCORE) Network, a global initiative aiming to advance CIT. STCC is the 27th member of the imCORE Network, the first from Southeast Asia and the first consortium to join.

STCC enters this prestigious Network leading a coalition of Singapore's public healthcare and research institutions in the translational cancer research ecosystem: National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), National University of Singapore (NUS) and Tan Tock Seng Hospital (TTSH).

Roche/Genentech-led, immunotherapy Centers Of Research Excellence (imCORE) Network strive to advance and extend the most promising new cancer immunotherapy treatment options for cancer patients. The imCORE Network unites both clinical and basic scientific experts from leading cancer research institutions worldwide alongside Roche and Genentech, in an open environment to collaborate on research, share information, expertise and technologies. The Network has already achieved significant breakthroughs, including accelerating the development of a pancreatic cancer vaccine candidate that is currently in Phase II trials.

STCC's participation in imCORE will catalyse and boost scientific exchange and collaborations across the full spectrum of CIT research. This includes pre-clinical, translational and real-world data (RWD) studies to solve cancer immunotherapy challenges, improve understanding of the tumour microenvironment in Asian populations, and accelerate the search for innovative cancer treatments.

STCC envision to establish Singapore as a cancer clinical trial hub and a global leader in translational cancer research, especially for cancers with higher prevalence or unique characteristics in Asian populations such as gastric cancer, head & neck cancer, lung cancer, liver cancer, clear cell ovarian carcinoma and Natural killer/T-cell lymphomas.